INS and type 1 diabetes mellitus: Furthermore, Vertex pharmaceuticals, running a Phase I/II clinical trial that transplants fully differentiated hPSC-derived β cells, infused into the hepatic portal vein of hypoglycemic patients with T1D, presented first set of results where they showed a 91% decrease in exogenous insulin administration for their first patient within 90 days, thus providing a huge breakthrough in the field of β-cell replacement therapy (NCT04786262).